Xiang Y - Search Results

1

Reduced B cell antigenicity of Omicron lowers host serologic response.

Tubiana J, Xiang Y, Fan L, Wolfson HJ, Chen K, Schneidman-Duhovny D, Shi Y. Tubiana J, et al. Among authors: xiang y. Cell Rep. 2022 Oct 18;41(3):111512. doi: 10.1016/j.celrep.2022.111512. Epub 2022 Sep 28. Cell Rep. 2022. PMID: 36223774 Free PMC article.

2

Chemical Cross-Linking and Mass Spectrometric Analysis of the Endogenous Yeast Exosome Complexes.

Xiang Y, Shen Z, Shi Y. Xiang Y, et al. Methods Mol Biol. 2020;2062:383-400. doi: 10.1007/978-1-4939-9822-7_18. Methods Mol Biol. 2020. PMID: 31768986

3

Versatile, Multivalent Nanobody Cocktails Efficiently Neutralize SARS-CoV-2.

Xiang Y, Nambulli S, Xiao Z, Liu H, Sang Z, Duprex WP, Schneidman-Duhovny D, Zhang C, Shi Y. Xiang Y, et al. bioRxiv [Preprint]. 2020 Aug 25:2020.08.24.264333. doi: 10.1101/2020.08.24.264333. bioRxiv. 2020. PMID: 32869034 Free PMC article. Updated. Preprint.

4

Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2.

Xiang Y, Nambulli S, Xiao Z, Liu H, Sang Z, Duprex WP, Schneidman-Duhovny D, Zhang C, Shi Y. Xiang Y, et al. Science. 2020 Dec 18;370(6523):1479-1484. doi: 10.1126/science.abe4747. Epub 2020 Nov 5. Science. 2020. PMID: 33154108 Free PMC article.

5

Integrative proteomics identifies thousands of distinct, multi-epitope, and high-affinity nanobodies.

Xiang Y, Sang Z, Bitton L, Xu J, Liu Y, Schneidman-Duhovny D, Shi Y. Xiang Y, et al. Cell Syst. 2021 Mar 17;12(3):220-234.e9. doi: 10.1016/j.cels.2021.01.003. Epub 2021 Feb 15. Cell Syst. 2021. PMID: 33592195 Free PMC article.

6

Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting novel and conserved epitopes.

Sun D, Sang Z, Kim YJ, Xiang Y, Cohen T, Belford AK, Huet A, Conway JF, Sun J, Taylor DJ, Schneidman-Duhovny D, Zhang C, Huang W, Shi Y. Sun D, et al. Among authors: xiang y. bioRxiv [Preprint]. 2021 Mar 10:2021.03.09.434592. doi: 10.1101/2021.03.09.434592. bioRxiv. 2021. PMID: 33758850 Free PMC article. Updated. Preprint.

7

Ubiquitination-mediated degradation of TRDMT1 regulates homologous recombination and therapeutic response.

Zhu X, Wang X, Yan W, Yang H, Xiang Y, Lv F, Shi Y, Li HY, Lan L. Zhu X, et al. Among authors: xiang y. NAR Cancer. 2021 Mar 22;3(1):zcab010. doi: 10.1093/narcan/zcab010. eCollection 2021 Mar. NAR Cancer. 2021. PMID: 33778494 Free PMC article.

8

Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses.

Nambulli S, Xiang Y, Tilston-Lunel NL, Rennick LJ, Sang Z, Klimstra WB, Reed DS, Crossland NA, Shi Y, Duprex WP. Nambulli S, et al. Among authors: xiang y. Sci Adv. 2021 May 26;7(22):eabh0319. doi: 10.1126/sciadv.abh0319. Print 2021 May. Sci Adv. 2021. PMID: 34039613 Free PMC article.

9

Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes.

Sun D, Sang Z, Kim YJ, Xiang Y, Cohen T, Belford AK, Huet A, Conway JF, Sun J, Taylor DJ, Schneidman-Duhovny D, Zhang C, Huang W, Shi Y. Sun D, et al. Among authors: xiang y. Nat Commun. 2021 Aug 3;12(1):4676. doi: 10.1038/s41467-021-24963-3. Nat Commun. 2021. PMID: 34344900 Free PMC article.

10

Llamanade : an open-source computational pipeline for robust nanobody humanization.

Sang Z, Xiang Y, Bahar I, Shi Y. Sang Z, et al. Among authors: xiang y. bioRxiv [Preprint]. 2021 Aug 4:2021.08.03.455003. doi: 10.1101/2021.08.03.455003. bioRxiv. 2021. PMID: 34373858 Free PMC article. Updated. Preprint.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7,346 results

Search Page